A carregar...
Evaluating ivosidenib for the treatment of relapsed/refractory AML: design, development, and place in therapy
Improvements in the last decade in understanding the molecular mechanisms underlying acute myeloid leukemia (AML) have emphasized that treatment regimens should be personalized with agents that can selectively target genetic abnormalities if present. Neomorphic mutations in isoform 1 of isocitrate d...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6314316/ https://ncbi.nlm.nih.gov/pubmed/30643428 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S182443 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|